Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer
JM Sun, KW Lee, JH Kim, YJ Kim… - Japanese Journal of …, 2009 - academic.oup.com
Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …
Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study
A Bearz, I Garassino, R Cavina, A Favaretto… - Lung cancer, 2008 - Elsevier
Several drugs have been approved for the treatment of patients affected by advanced non-
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC cancer, 2008 - Springer
Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
Pemetrexed in advanced non-small-cell lung cancer
AD Fuld, KH Dragnev, JR Rigas - Expert Opinion on …, 2010 - Taylor & Francis
Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
YH Kim, M Hirabayashi, Y Togashi, K Hirano… - Cancer chemotherapy …, 2012 - Springer
Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …
[HTML][HTML] Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - Elsevier
Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer
MH Cohen, R Justice, R Pazdur - The oncologist, 2009 - academic.oup.com
Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …
Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis
K Al-Saleh, C Quinton, PM Ellis - Current Oncology, 2012 - mdpi.com
Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non–small …
WHW Schuette, A Gröschel, M Sebastian, S Andreas… - Clinical lung cancer, 2013 - Elsevier
Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non–small-cell lung cancer: results of the GOIRC 02-2006 randomized …
A Ardizzoni, M Tiseo, L Boni, AD Vincent… - Journal of clinical …, 2012 - ascopubs.org
Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …